Lv1
10 积分 2025-03-11 加入
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer
4小时前
求助中
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
3个月前
已完结
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
3个月前
已完结
Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx)
3个月前
已关闭
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
3个月前
已完结
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma
3个月前
已完结
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
3个月前
已完结
Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur Urol 84(5) (2023) 449–454]
3个月前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
3个月前
已完结
Epidemiology of Renal Cell Carcinoma: 2022 Update
3个月前
已完结
皖公网安备34019202002308
